Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
Burgard C, Hein C, Blickle A, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F. Burgard C, et al. Among authors: bartholoma m. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):885-895. doi: 10.1007/s00259-023-06476-x. Epub 2023 Oct 27. Eur J Nucl Med Mol Imaging. 2024. PMID: 37889298 Free PMC article.
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
Burgard C, Engler J, Blickle A, Bartholomä M, Maus S, Schaefer-Schuler A, Khreish F, Ezziddin S, Rosar F. Burgard C, et al. Among authors: bartholoma m. Front Med (Lausanne). 2024 Jan 17;10:1339160. doi: 10.3389/fmed.2023.1339160. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38298510 Free PMC article.
[89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S. Rosar F, et al. Among authors: bartholoma m. Cancer Imaging. 2024 Feb 22;24(1):27. doi: 10.1186/s40644-024-00671-1. Cancer Imaging. 2024. PMID: 38389092 Free PMC article.
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617.
Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, Bartholomä M, Stemler T, Ezziddin S, Rosar F. Schaefer-Schuler A, et al. Among authors: bartholoma m. Theranostics. 2024 Feb 24;14(5):1829-1840. doi: 10.7150/thno.92273. eCollection 2024. Theranostics. 2024. PMID: 38505615 Free PMC article.
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me.
Schreck MV, Burgard C, Schmidtke A, Hierlmeier I, Stemler T, Maus S, Rosar F, Jung M, Speicher A, Ezziddin S, Holland JP, Bartholomä MD. Schreck MV, et al. Among authors: bartholoma md. Mol Pharm. 2023 Dec 4;20(12):6463-6473. doi: 10.1021/acs.molpharmaceut.3c00852. Epub 2023 Nov 18. Mol Pharm. 2023. PMID: 37978936
Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations.
Burgard C, Rosar F, Marlowe RJ, Bartholomä M, Dewes S, Schaefer-Schuler A, Linxweiler J, Khreish F, Ezziddin S. Burgard C, et al. Among authors: bartholoma m. Cancers (Basel). 2023 May 3;15(9):2592. doi: 10.3390/cancers15092592. Cancers (Basel). 2023. PMID: 37174058 Free PMC article.
63 results